IXICO (LSE:IXI) Momentum Rank : 0 (As of May. 13, 2024)

View and export this data going back to 1996. Start your Free Trial

What is IXICO Momentum Rank?

IXICO has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

IXICO Momentum Rank Related Terms

Thank you for viewing the detailed overview of IXICO's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

IXICO (LSE:IXI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IXICO PLC (LSE:IXI) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

PHYOF:USA

Address

15 Long Lane, 4th Floor, Griffin Court, London, GBR, EC1A 9PN

Website

https://www.ixico.com

IXICO PLC is a UK-based company engaged in providing clinical trial services and technology to evaluate imaging endpoints to pharmaceutical companies. Its therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, Progressive Supranuclear Palsy, and Other Rare Neurological Diseases. Services offered by the company are Early Phase Clinical Development, Late Phase Clinical Development, Post-Marketing, and Consultancy. The company's geographical segments include the United States, Switzerland, the United Kingdom, the Netherlands, Ireland and other- Europe. The Company work with healthcare organizations across the entire clinical research journey, for drug development analytics, medical imaging operations and post-marketing surveillance.

IXICO (LSE:IXI) Headlines

No Headlines